New data for Vibativ (telavancin)for MRSA and other difficult to treat infections- Theravance BioPharma

Theravance Biopharma, Inc. announced new positive data from several studies of Vibativ (telavancin) confirming the product's in vitro potency against isolates from a range of difficult-to-treat infections. The findings further supplement the extensive and well-documented evidence demonstrating greater in vitro activity for Vibativ against methicillin-resistant Staphylococcus aureus (MRSA) and other difficult-to-treat clinical pathogens as compared to antibiotics such as vancomycin, daptomycin and linezolid.

Results from these studies were presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in San Diego, CA, on September 17 - 21, 2015.

Highlights from data presentations include:

1.Researchers showed that Vibativ possessed the greatest in vitro activity of all antibiotics evaluated against a broad collection of contemporary Gram-positive clinical isolates that caused complicated skin and skin structure infections (cSSSIs) in U.S. hospitals. Data showed that the minimum inhibitory concentrations (MICs) for Vibativ were eight-fold lower than for daptomycin and 16-fold lower than for vancomycin and linezolid against all Staphylococcus aureus (S. aureus) strains, including MRSA and methicillin-susceptible Staphylococcus aureus (MSSA) subsets. MICs are a common measure used to express an antibiotic's in vitro potency.

2. Data from a second study demonstrated that Vibativ possessed the greatest in vitro activity of all antibiotics evaluated against a broad collection of contemporary Gram-positive cocci from Canadian hospitals.Vibativ showed greater in vitro potency than vancomycin, daptomycin and linezolid against such pathogens as MRSA, vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA).

3. Data from additional studies highlighted the potential of Vinativ in addressing serious infection types with significant unmet medical need and critical treatment challenges. For example, Vibativ demonstrated greater in vitro activity against biofilm-producing MRSA, as compared to vancomycin, daptomycin, teicoplanin, and ceftaroline.

Furthermore, results showed Vibativ to be significantly more effective than vancomycin and daptomycin in animal models of infective endocarditis (IE) caused by MRSA. In these IE models, Vibativ was significantly better than daptomycin at reducing the levels of MRSA found in target tissues and producing a significantly higher percentage of target tissues that were classified as culture-negative. Vancomycin was relatively ineffective in both of these areas.